News

US FDA pauses Gilead trials testing experimental HIV pill combination
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
US FDA places clinical hold on Gilead trials testing HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
BioSpace4d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
GlobalData on MSN3d
Gilead hit with FDA clinical hold for batch of HIV trials
Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
Fierce Biotech4d
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
eNCA6hOpinion
South Africa at a crossroads: Can it keep up with a changing global health system?
The health crisis has spilled into South Africa’s universities and research hubs. Institutions that once hosted major NIH- ...
Bloomberg L.P.4d
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients ...
Gilead: FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182
Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...
Why Gilead Sciences Stock Tumbled on Tuesday
Gilead was putting the two drugs through their paces in a series of clinical trials, which were at various stages. The ones in the mid-to-late cycles were testing the pair against its currently ...